• News
  • BioTech

Cardium announces positive data for heart disease treatment

Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report Tuesday at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

The presentation at the 2014 BIO International Convention, now underway at the San Diego Convention Center, will be by Christopher Reinhard, Taxus Cardium's CEO and Cardium Therapeutics' co-founder.

Cardium will report on positive safety and statistically significant efficacy data from a randomized, multi-center, controlled study's primary registration endpoint of improvement in cardiac perfusion (blood flow) with Generx compared to the control group.

User Response
0 UserComments